Ray Therapeutics Targets Vision Restoration With Optogenetics

Ray Therapeutics is a Berkeley clinical-stage biotechnology company building optogenetic gene therapies for degenerative retinal diseases. Founded in 2021 and led by co-founder and CEO Paul Bresge, the company is developing a way to make surviving retinal neurons responsive to light after the photoreceptors that normally perform that job have been lost.

Its lead program, RTx-015, is being studied in the Phase 1 ENVISION trial for retinitis pigmentosa and choroideremia. A second program, RTx-021, targets Stargardt disease and geographic atrophy. The portfolio places Ray Therapeutics inside a difficult but consequential market: restoring useful visual signals for people whose disease has progressed beyond the point where mutation-specific replacement alone may solve the practical problem.

Ray matters now because its scientific thesis has moved into human testing while the company builds the capital, regulatory capacity, and development team required for a longer clinical journey. That combination does not prove the therapy works. It does show that optogenetic vision restoration is moving from an elegant laboratory concept into a program that can be measured, challenged, and improved in patients.

About Ray Therapeutics

Ray Therapeutics was founded in 2021 with a mission to restore vision for people with blinding diseases. The company's technology uses gene therapy to deliver a bioengineered light-sensitive protein to retinal cells that may survive after photoreceptors degenerate. Those surviving neurons could then respond to light and transmit a new visual signal toward the brain.

The approach is mutation-independent. Retinitis pigmentosa can arise from many genetic causes, while Ray's lead program is designed around the downstream loss of photoreceptor function. Instead of matching a therapy to one causative mutation, RTx-015 attempts to repurpose retinal ganglion cells that remain in the visual pathway.

That distinction widens the theoretical reach of the platform, but it also raises the standard of proof. Making a cell light-sensitive is only the opening move. The signal must be safe, strong, stable, and interpretable enough for a person's visual system to turn it into function.

The Pipeline: RTx-015 and RTx-021

Ray's pipeline centers on two investigational programs. RTx-015 targets retinitis pigmentosa and other inherited retinal diseases by delivering an optogenetic protein to retinal ganglion cells. RTx-021 targets retinal ON-bipolar cells and is being developed for Stargardt disease and geographic atrophy.

The lead clinical study is ENVISION, a Phase 1, open-label, non-randomized trial of a single intravitreal injection of RTx-015 in one eye. ClinicalTrials.gov currently lists the study as active but not recruiting, with actual enrollment of 10 participants and planned follow-up over five years.

This is where the company story becomes less cinematic and more important. A vision-restoration therapy has to clear several different hurdles: delivery, tolerability, immune response, light sensitivity, durability, and functional measurement. Visual acuity, navigation, object recognition, contrast, and light perception are not interchangeable outcomes. Early clinical development has to learn which changes are real and which ones matter outside an exam room.

Capital Built Around the Evidence Chain

Ray Therapeutics has announced $231M in private financing since 2022. The company raised a $6M seed round led by 4BIO Capital, a $100M Series A led by Novo Holdings, and an upsized $125M Series B led by Janus Henderson Investors in April 2026.

The Series B added Adage Capital Management, Franklin Templeton, Invus, and Marshall Wace alongside returning investors including 4BIO Capital, Deerfield Management, MRL Ventures Fund, Norwest, Novo Holdings, and Platanus. Ray said the financing would support late-stage development and commercial readiness for RTx-015 plus clinical studies for RTx-021.

Public research funding has occupied a different part of the same path. The California Institute for Regenerative Medicine lists three Ray awards totaling $15,973,707, including a $7,975,224 clinical-stage grant for RTx-015. The grants are non-dilutive support for defined research and clinical work, not additional venture rounds.

Leadership for a Clinical-Stage Build

Ray's current leadership team reflects the shift from platform formation toward clinical and regulatory execution. Paul Bresge previously led jCyte, another retinal-disease biotechnology company, and helped complete a $252M licensing agreement with Santen Pharmaceutical.

The executive team includes Chris Whitmore, CPA, as CFO; Peter Francis, MD, PhD, as Chief Medical & Scientific Officer; Jenny Holt as Chief Development Officer; Mike Murtagh as Chief Regulatory Officer; and Sonya Weigle as Chief of Staff and Chief Corporate Affairs Officer. Their remit spans medical strategy, development operations, finance, regulatory planning, and the organizational work required to move a rare-disease program toward later-stage study.

Ray reported that RTx-015 received FDA Regenerative Medicine Advanced Therapy designation and European Medicines Agency Priority Medicines designation in April 2026. Those designations can create more structured regulatory dialogue. They are not approvals and do not replace clinical evidence.

Why Hiring Momentum Matters

Ray's careers page says the company is actively seeking candidates and points applicants to current opportunities on LinkedIn. The company describes its culture as patient-guided, collaborative, inclusive, and intellectually curious.

The hiring signal matters because clinical-stage biotechnology gets operationally heavier as the evidence matures. Dose escalation, data management, manufacturing, quality, regulatory submissions, and long-term follow-up require a different organizational machine than preclinical discovery. A larger team is not proof of program success. It is evidence that the company is preparing to answer more expensive questions under greater scrutiny.

What Ray Therapeutics Signals for Vision Restoration

Ray Therapeutics sits at the intersection of gene therapy, neuroscience, ophthalmology, and medical-device-like questions about how patients perceive and use a new signal. The company is not merely trying to preserve cells. It is asking whether surviving retinal circuitry can be assigned a new job after disease has erased the original input.

That makes the market signal larger than one biotechnology company. Mutation-specific gene replacement has already shown that inherited retinal disease can be treated in defined populations. Optogenetics is testing whether a downstream, mutation-independent approach can reach people after substantial photoreceptor loss.

For founders and investors, Ray illustrates how platform ambition becomes credible through a sequence of narrower commitments: one delivery route, one dose-escalation study, one measurable safety profile, and one set of patient outcomes at a time. For operators, the opportunity is equally clear. The science may begin with light-sensitive proteins, but progress depends on the people who can translate that signal into manufacturing, clinical evidence, regulatory language, and eventually a therapy patients can use.